PUMA BIOTECH (PBYI) Director Cesano Exercises Options, Sells Shares

What Happened
Director Alessandra Cesano both exercised stock options and sold shares on 2026-09-14. She exercised options to acquire 50,000 shares at $2.93 per share (cash cost $146,500). The filing also shows an open-market sale of 62,150 shares at a weighted average price of $9.12, generating approximately $566,994 in proceeds. The report includes a separate line showing a disposition of 50,000 derivative shares at $0; the filing does not explain the $0 consideration.

Key Details

• Transaction date: 2026-09-14 (filed 2026-09-16; filing appears timely within the 2-business-day rule).
• Option exercise: 50,000 shares acquired at $2.93 — total reported cost $146,500. (Stock option fully vested — footnote F3.)
• Open-market sale: 62,150 shares sold at a weighted average price $9.12 (range $9.03–$9.20) — proceeds ~$566,994. (Footnote F2 explains weighted-average pricing and availability of per-price breakdown on request.)
• Derivative disposition: 50,000 shares listed as disposed at $0 (filing does not specify reason).
• 10b5-1: The sale was executed under a prearranged 10b5-1 plan adopted 06-15-2026 (footnote F1).
• Shares owned after the transactions: Not specified in the provided filing.

Context

• The filing shows both an option exercise (an acquisition) and an open-market sale on the same date. That combination can reflect routine option exercises and planned sales (the 10b5-1 note indicates the sale was prearranged), but the filing itself gives no explanation of motives.
• The $0 disposition of derivative shares frequently represents net settlement or withholding related to exercises, though the form does not state the reason.
• For retail investors, purchases (option exercises) indicate an insider acquiring stock exposure; sales under a 10b5-1 plan are typically preplanned and not necessarily a contemporaneous signal of sentiment.